Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

• Status: Withdrawn
• Trial end date: 2021-01-29

Summary

The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: R-Pharm
• Collaborators: Covance; Cromos Pharma LLC; Cromos Pharma, LLC